Purpose: There is little published data on the technique and results of whole-field (WF) sequential intensity-modulated radiotherapy (S-IMRT) for patients with head-and-neck squamous cell carcinoma (HNSCC). We report the treatment outcomes, adverse events (AEs), and dosimetric parameters in local-regional advanced (LRA) HNSCC patients treated with the WF S-IMRT technique.
C oncurrent chemoradiotherapy is commonly used for localregional advanced (LRA) head-and-neck squamous cell carcinoma (HNSCC). 1 Although concurrent chemoradiotherapy improves treatment outcomes, it results in higher treatment-induced acute and chronic adverse events (AEs). 2, 3 Intensity-modulated radiation therapy (IMRT) has been increasingly adopted as an effective radiation technique that provides excellent local-regional control (LRC), fewer treatment-induced AEs, and improved quality of life. [4] [5] [6] [7] [8] [9] IMRT techniques vary according to institutional preference, with most institutions using either simultaneous integrated boost (SIB) or sequential-IMRT (S-IMRT). SIB-IMRT uses multiple radiation beams to simultaneously irradiate the tumor target and adjacent areas to different doses during a single treatment session, resulting in higher dose per fraction for gross target volume (GTV), and lower doses per fraction for areas at low and intermediate risk of harboring microscopic disease. S-IMRT uses sequentially shrinking fields with the same fraction size throughout the entire course of treatment. Whole-field (WF) IMRT entails treating the entire HNSCC target volume (TV) without a junction between upper and lower neck fields.
SIB-IMRT requires 1 treatment plan and is more conformal, 10 whereas S-IMRT requires multiple plans but delivers the same fraction size used historically, as reported in published studies with longer follow-up. Because of its larger fraction size, the SIB technique results in a higher biological dose to normal tissues embedded in primary TV, and has the potential for increased AEs. 11 However, the SIB-IMRT delivers smaller fraction size (1.65 to 1.8 Gy/fraction) to lowrisk and intermediate-risk microscopic disease in the neck potentially reducing normal tissue toxicity embedded in these targets. This advantage is offset due to higher total dose delivered to these targets in SIB-IMRT technique, to achieve comparable Biological Equivalent Dose delivered with S-IMRT using conventional fractionation.
There is a paucity of published data on the technique and treatment outcome of WF S-IMRT. 9 In our study, we report treatment outcomes, acute and chronic AEs, and dosimetric parameters in the largest series of LRA HNSCC patients treated with WF S-IMRT technique.
MATERIALS AND METHODS

Patient Selection and Staging
Our Institutional Review Board approved this study, which includes patients with LRA HNSCC (oral cavity, oropharynx, nasopharynx, hypopharynx, larynx, and unknown primary). These patients presented to our department between January 2003 and December 2010 and were treated consecutively, either postoperatively or definitively, using WF S-IMRT with or without chemotherapy.
All patients had a complete physical examination, blood workup, and imaging studies, including computed tomography (CT), magnetic resonance imaging, and positron emission tomography (PET), as indicated. Feeding was assured and, when necessary, a feeding tube (FT) was used. Patients received a thorough dental evaluation and pretreatment swallowing study before they began treatment.
Treatment Planning
All patients were immobilized with an aquaplast mask. All patients underwent a planning CT scan with the majority receiving IV contrast. CT imaging included the region between the vertex superiorly and the carina inferiorly, with a slice thickness of 3 mm.
TVs
Definitive WF S-IMRT
The GTV included clinically and/or radiologically visible disease. Clinical target volume 1 (CTV 1 ) included GTV and high-risk and low-risk elective nodal regions in the neck, with a 1 to 2 cm margin. Clinical target volume 2 (CTV 2 ) included GTV and high-risk elective nodal region with 0.75 to 1.5 cm margin. Clinical target volume 3 (CTV 3 ) included GTV expanded by 0.5 to 1 cm to cover any microscopic soft-tissue extension.
Three planning target volumes (PTV 1-3 ) were created that encompassed corresponding CTV with a margin of 3 to 5 mm to account for setup and patient movement errors. Later on, for the sake of simplicity, we only outlined GTV and 3 PTVs, described above. We used the axial images from the planning CT to identify nodal levels in the neck, as described by Som et al. 12 We used the historical data primarily for neck metastases, summarized by Chao et al 13 to stratify nodal disease as high risk and low risk for elective neck irradiation.
Postoperative WF S-IMRT
The surgical bed was defined as the area of preoperative GTV and the operated area that included the resected tumor, the lymph nodes involved, and postsurgical changes. CTV 1 included the surgical bed and regional high-risk and low-risk elective nodal chain with a 1 to 2 cm margin. CTV 2 included the surgical bed and high-risk elective nodal chain with a 1 to 2 cm margin. In patients with high-risk features such as extracapsular extension, the surrounding soft tissue was included with a generous margin. Each CTV was expanded by 3 to 5 mm to create PTV 1 and PTV 2 ; later on, for simplicity sake, the surgical bed and 2 to 3 PTVs were created. In both definitive and postoperative S-IMRT, TVs were drawn 2 to 3 mm deeper to the skin surface to spare dermal structures unless the gross tumor or extracapsular extension was very close to the skin.
Dose Specifications
Radiation doses were sequentially prescribed using conventional fractionation of 180 to 200 or 150 cGy bid according to institutional protocol. Typically, low-risk target volumes (PTV 1 ) received 45 to 50 Gy, intermediate-risk to high-risk targets (PTV 2 ) received 56 to 66 Gy, and the gross tumor with expansion (PTV 3 ) was treated to 70 to 72 Gy. Three separate IMRT plans corresponding to each PTV were generated and whole-neck IMRT was used ( Fig. 1 ). Every attempt was made to ascertain that the prescribed dose covered Z95% of the TV, with the hot spot not exceeding 10% of the prescribed dose.
Dose Optimization
For all target PTVs, maximum dose was used to restrict dose to <110% of the prescribed dose, whereas maximum dose-volume histograms (DVH) was used to restrict the 105% dose volume inside PTV and minimum DVH used to ascertain that at least 95% of the PTV is covered by 100% of the prescribed dose.
For normal structures, a combination of max dose, max DVH, and max Equivalent Uniform Dose were used as optimization criteria. To achieve a clinically acceptable plan, the objective values and weights were iteratively adjusted with the following order of priority: (1) minimize the maximum dose to the serial organs such as the spinal cord and brainstem; (2) minimize the mean dose to the swallowing organs at risk (OARs) such as the pharyngeal constrictors, larynx, and postcricoid esophagus; and (3) minimize the mean dose to parotids and oral cavity.
OARs
For each patient, 27 OARs were outlined and DVH were generated. OARs included: brain stem, pituitary gland, spinal cord, cochlea, optic nerve, optic chiasm, eyes, parotid glands, submandibular glands, oral cavity, oropharynx, base of the tongue, entire larynx, supraglottic larynx, glottis larynx, hyoid bone, postcricoid esophagus, cervicothoracic esophagus, lips, mandible, superior, middle, inferior, and combined pharyngeal constrictors, carotid vessels, thyroid gland, and the brachial plexus. The doses to each TV and OARs were reported and analyzed. Pinnacle inverse planning system versions 6.2b, 7.6c, 8.0m, and 9.0 using computerized optimization (Philips Radiation Oncology Systems, Fitchburg, WI) were used to generate 3 separate plans for PTV 1 , PTV 2 , and PTV 3 , as well as cumulative DVHs.
Treatment plan statistics for relevant OARs were exported from the Pinnacle 3 treatment planning system file of each patient, using a customized script that deposited the data into text files. The statistics were taken from composite trials that contained beam data from all PTVs used in a given patient's treatment. For all OARs, volume and maximum, minimum, and mean doses were exported. For ease of use, data were then transferred to Excel files using a MATLAB program, although this program performed no mathematical manipulation.
The median, mean, minimum, maximum, and SD of the maximum and mean doses in cGy, as well as median and mean volumes in cm 3 for all OARs, were collected and reported.
Follow-up
Patients were seen for follow-up 1 month after radiation was completed, then approximately every 3 months during the first year, every 4 months during the second year, and every 6 months for the subsequent 5 years, with yearly follow-up thereafter. Physical examination included fiberoptic laryngoscopy at each follow-up visit. The first imaging study (CT images and/or FDG-PET) was obtained 1 to 3 months after treatment to assess response and thereafter as indicated; for all patients, an imaging study was usually performed once a year.
Toxicities were categorized into acute toxicity according to the Common Terminology Criteria (CTC) for AEs, version 3.0 (< 90 d posttreatment), and chronic toxicity according to the Radiation Therapy Oncology Group (RTOG) scale. To assess the incidence of severity of complications and their resolution during follow-up, the worst chronic toxicity and toxicity at the most recent follow-up were reported. Toxicities were registered at each treatment check and at each follow-up visit. Toxicities were coded for skin, mucosa, dysphagia, salivary gland, mandible, thyroid function, larynx, pain, and weight loss. Other variables included G-tube placement, cervical/esophageal stricture formation, or any other significant toxicity a patient experienced.
Statistical Analyses
Descriptive statistics were shown in the form of frequencies, and percentages for categorical variables, and medians, means, SDs, minimums, and maximums for continuous variables. Univariate logistic regression was used to relate the occurrence of death, local-regional recurrence, or aspiration according to patient or radiation-dose parameters. Relapse-free survival (RFS) is defined as the time from first radiation treatment to any local, regional, or distant tumor progression, whichever occurred first. LRC is defined as the time from first radiation treatment to any local or regional tumor progression, whichever occurred first. Distant metastases-free survival (DMFS) is defined as the time from first radiation treatment to any distant tumor progression. Overall survival (OS) was measured from the first radiation treatment to death as a result of any cause. OS curves were estimated using the Kaplan-Meier method and compared across site and stage using the log-rank test. RFS, LRC, and DMFS were estimated using the method of cumulative incidence 14 and differences were assessed by the Gray test. 15 
RESULTS
Patient and Tumor Characteristics
From January 2003 to December 2010, 103 LRA HNSCC patients (stages III, IVA, and IVB) were treated with WF S-IMRT with (99 patients) or without (4 patients) concurrent chemotherapy. The median follow-up for all patients was 40 months (range, 4 to 95 mo; mean, 42.3 mo). Table 1 lists patient demographics, including sex, age, race, smoking history, performance status, tumor characteristics including site and stage distribution, and treatment modalities.
Radiation Therapy
The median cumulative radiation dose was 70 Gy (range, 60 to 75 Gy; mean, 69.35 Gy; SD 4.01 Gy) and the median treatment duration was 50 days (range, 41 to 91 d; SD 7.6 d). Every patient had WF S-IMRT with the same fraction size throughout the treatment course. All patients who had bid IMRT had 1.5 Gy/fraction, according to institutional protocol. Patients with once-a-day IMRT had 1.8 to 2 Gy/fraction, with the majority of patients receiving 2 Gy/fraction. The maximum and mean doses in cGy and mean and median volumes for all OARs are shown in Table 2 .
Treatment Outcomes
Of the 103 patients, 3 patients (2.9%) had local-regional failure only, 9 patients (8.7%) had DM only, and 3 patients (2.9%) had both local-regional failure and DM. The median 2-and 5-year OS, RFS, LRC, and DMFS are stratified and detailed in Table 3 and Figure 2 . The log-rank and Gray tests showed no statistical significance for stratification by stage or tumor site. Smokers had a significantly higher incidence of death (odds ratio = 2.26, P = 0.003) and local-regional recurrence (odds ratio = 2.6, P = 0.037). 
AEs
All patients in our study were followed regularly to monitor acute and chronic AEs. Table 4 shows acute and chronic AEs (worst and at last follow-up visit) based on CTCAE version 3.0 and RTOG scale, respectively. None of the patients had spinal cord injury or brachial plexopathy. Two patients (1.9%) had mandibular osteoradionecrosis; one was treated by hyperbaric oxygen and the other had mandibular resection and a fibula flap. Four patients had aspiration (3.88%), with smoking significantly associated with aspiration (odds ratio = 1.87, P = 0.021). FTs were used in 35 patients (34%) during or soon after their treatment course; only 3 patients (2.9%) were maintained on FTs during their most recent follow-up visit.
Logistic regression was used to find a statistically significant association between aspiration and maximum radiation dose delivered to superior, middle, inferior, and combined pharyngeal constrictors; base of the tongue; supraglottic and whole larynx (P = 0.011, 0.01, 0.01, 0.013, 0.011, 0.012, and 0.013, respectively); and mean doses to middle and inferior pharyngeal constrictors and supraglottic larynx and whole larynx (P = 0.033, 0.05, 0.025, and 0.02, respectively). In addition, there was a statistically significant association between grade 3 chronic dysphagia and maximum RT dose delivered to postcricoid esophagus (P = 0.05) and mean RT dose delivered to the cervicothoracic esophagus (P = 0.005). There was a statistically significant association between mean dose delivered to combined parotid glands and xerostomia (P = 0.039), but no significant association between maximum or mean doses and combined submandibular glands.
DISCUSSION
The majority of published data on the use of IMRT for the treatment of HNSCC are based on the SIB technique. [5] [6] [7] [8] With the introduction of IMRT, to prevent unintended consequences of new technology, we used S-IMRT to deliver historically proven cumulative dose of Z7000 cGy to areas of gross disease, and 4600 and 6000 cGy to areas of low-risk and high-risk microscopic disease, respectively, with fraction size of 180 to 200 cGy throughout the treatment course. In 22% of the patients reported in this study, 150 cGy bid fractionation was used as per an institutional protocol. We also used WF S-IMRT to prevent dosimetric and setup uncertainties at the junction between the upper and lower neck fields. At the start, our radiation fields were generous. However, gradually, we started to reduce dose to salivary glands, oral cavity, and OARs involved in swallowing. In patients with positive level II neck nodes, we did not attempt to spare ipsilateral parotid and submandibular glands that might explain the relatively higher mean doses delivered to the salivary glands in our cohort.
In our study, the 2-year LRC, DMFS, RFS, and OS were 97%, 91%, 90%, and 94%, respectively; and the 5-year LRC, DMFS, RFS, and OS were 93%, 89%, 84%, and 77%, respectively. Recently, Garden et al 5 reported a retrospective analysis of 776 oropharyngeal cancer patients (OPC) treated with IMRT during the period between 2000 and 2007; 5-year LRC, overall recurrence-free survival, and OS were 90%, 82%, and 84%, respectively. The majority of those patients (89%) were treated with SIB IMRT with split beam to treat the lower neck. Similar to our study, smoking was associated with poorer survival (P < 0.001). Chao et al 6 reported the 2-year LRC of 79% and 90% in 126 HNSCC patients who were treated with split-field IMRT using the SIB technique for definitive and postoperative treatments, respectively.
Feng et al 7 reported a prospective study that included 73 patients with stages III to IV OPC treated with chemo-IMRT using the WF SIB technique. At a median follow-up of 36 months, 3-year disease-free survival and LRC were 88% and 96%, respectively. Our results are comparable with the 3-year actuarial LRC, DMFS, PFS, and OS rates of 92%, 86%, 82%, and 91%, respectively, for 41 LRA HNSCC patients treated with IMRT; and most (32 patients) were treated with the SIB technique, as reported by Lee et al. 8 Yao et al 9 reported comparable 2-year LRC (92%), DMFS (87%), and OS (85%) for 150 HNSCC patients who were treated using different IMRT techniques; most patients had LRA disease (85.4%). In this report, patients with OPC had significantly better (P = 0.005) 2-year LRC (98%) than patients with oral cavity (78%) and laryngeal cancer (85%), although our study showed no significant differences among patients in whom different tumor sites (P = 0.42) were treated.
The WF S-IMRT-induced AEs in our study were relatively tolerable and acceptable. None of the patients had spinal cord or brachial plexus damage or any grade 4 acute or chronic AEs. Our data regarding the need of FTs during the acute phase of treatment and on follow-up (34%) compares to the 47% reported by Garden et al 5 and the 29% reported by Feng et al. 7 In our study, at the last follow-up visit, only 3 patients (3.1%) required FTs and 6 patients (6.2%) had grade 3 xerostomia. Our study showed an incidence of mandibular osteoradionecrosis (1.9%) comparable with that reported by Garden et al 5 (3.9%). Our study also showed the association between the maximum and mean RT doses delivered to pharyngeal constrictors and the larynx (specifically supraglottic larynx), and the likelihood of treatment-induced aspiration.
Our study and several other reports have shown that IMRT provides excellent LRC and acceptable AEs, and improves quality of life. [5] [6] [7] [8] [9] Dosimetry studies based on 5 HNSCC patients and 1 schematic HNSCC example have shown that, in terms of equal PTV coverage, SIB is more conformal than S-IMRT. 10, 11 However, Lamers-Kuijper et al 16 evaluated 50 patients and concluded that S-IMRT results in a better treatment plan for most patients compared with SIB-IMRT, if the boost PTV is >1 cm away from at least 1 parotid gland. In certain cases, more conformity and steep dose gradients may result in marginal misses. [17] [18] [19] From the beginning of our study we did not try to spare ipsilateral parotid glands in our patients with positive level II lymph nodes, therefore none of our patients had ipsilateral marginal failure in the parotid region. Dabaja et al 20 and Mendenhall and Mancuso 18 reported the advantage of WF-IMRT if there was uncertainty at the match line, compared with the traditional half-beam split-field IMRT, where the tumor and upper neck are being treated with IMRT and the lower neck is treated with a matching anterior beam. WF S-IMRT eliminates possible junction uncertainties associated with the split-field SIB technique, particularly in patients with large-neck disease and a low-lying primary tumor site. Daly et al 21 have reported a failure at the junction between upper and lower neck fields. However, WF IMRT can result in an increased radiation dose to midline structures in the lower neck field. 22 We believe that SIB and WF S-IMRT are not competing but complementary techniques, and that many factors should be considered when selecting the technique that best suits each clinical scenario to achieve an individualized treatment plan. These factors include the expertise of the radiation oncologist; the experience of the institution; the availability of resources and personnel (WF S-IMRT requires the development of 2 to 3 IMRT plans per patient vs. a single IMRT plan in SIB); patient preference (SIB might entail a slightly shorter treatment duration); and the tumor location, including critical OARs in primary TV, with the SIB technique resulting in a higher, biologically equivalent, normalized total dose to these OARs. 11 
CONCLUSIONS
Our study reports that WF S-IMRT results in excellent tumor control and an acceptable toxicity profile in this largest series of LRA HNSCC patients. A controlled comparison of SIB versus S-IMRT would be of interest.
